Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow MDGL by emailGet an email when MDGL pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MDGL, unsubscribe in one click. Privacy
📣 What MDGL Says Is Next
in 2027 · “Baseline characteristics of patients from the OLE F4c cohort are similar to patients enrolled in the ongoing MAESTRO-NASH OUTCOMES trial which is expected to read out topline data in 2027.”
Company press release, Feb 19, 2026 · SEC filing
this year · “Madrigal plans to conduct a drug-to-drug interaction study with Rezdiffra and consult with the FDA on design of a Phase 2 combination trial this year. 2025 Highlights”
Company press release, Feb 19, 2026 · SEC filing
in 2026 · “IND-enabling activities in initial candidates will begin in 2026.”
Company press release, Feb 19, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full MDGL picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MDGL and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.